top of page
Contact Us

General Surgery & Minimally Invasive Devices

BSC® supports surgical device manufacturers with statistical strategies that demonstrate procedural benefit while addressing FDA's safety expectations. From robotic systems to minimally invasive instruments, we help you build compelling evidence for both regulatory approval and clinical adoption.

Overview


BSC supports surgical device development across general surgery, including laparoscopic systems, robotic surgery platforms, surgical staplers and sealants, energy-based devices, and surgical navigation systems. Our experience spans both open and minimally invasive surgical techniques.

Specialized Capabilities


Surgical outcome composite endpoint design. Handling of surgeon learning curves in statistical models. Non-inferiority designs for surgical device equivalence. Complication rate analysis with appropriate risk adjustment. Economic endpoint integration (length of stay, resource utilization).

Regulatory Experience


We understand FDA expectations for surgical devices, including appropriate concurrent controls, handling of surgeon variability, and demonstration of device safety across skill levels. Our team has experience with both substantial equivalence (510(k)) and PMA pathways.

Representative Studies


  • Surgical staplers and closure devices.
  • Energy-based surgical devices (electrosurgery, ultrasonic).
  • Surgical mesh and fixation products.
  • Surgical navigation and guidance systems.
  • Laparoscopic and robotic surgical systems.
Previous Therapy Area
Next Therapy Area

BSC® Differentiator

What Sets us Apart

Submission Grade Experience

Regulatory-first biostatistics

Support built specifically for FDA-facing programs, from early feasibility through submission and post-market requirements.

Direct communication, faster turn around

Our biostatisticians write the SAP and run the analysis. One person owns both — no separate programmer, no project manager in between.

Versatile Solutions

Engage us for a focused analysis or a full submission, We size the work to the problem.

Proven FDA Experience

Hands-On Experience with FDA Pathways, statistical reviews, and regular interactions, reducing risk and rework.

WHAT CLIENTS SAY

“They listen the first time. I’ve never had to go back and respell out what I needed." 


”They work to understand the problem and leverage the information that is already there.”

Former FDA Regulator

WHAT CLIENTS SAY

"Battle ground tested."


"There is nothing that David and team haven’t seen over the years – the good, bad, and ugly.”

Vice President, Clinical Operations

WHAT CLIENTS SAY

"Get stuff done when you have to do something no one else has done before."


"They aren’t afraid to tackle difficult scenarios in compressed timelines."

CEO, Medical Device Company

BSC® Insights

Get Regulatory Insights

from BSC® 

May 17, 2026

Private Equity Bought Your Sponsor.

Industry Landscape

May 9, 2026

What Is the EMA?

FDA Regulatory Strategy

March 9, 2026

Clinical Data Presentations for Orthopedic Device Applications

FDA Regulatory Strategy

bottom of page